More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

Feb 15, 2021 at 10:44 PM EST · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Feb 15, 2021 at 10:44 PM EST · 5 pages · English

On 6ix: 6ix.com/news/neuren-adds-prader-willi-syndrome-to-nnz-2591-pipeline

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

  • Successful Phase 1 trial for Neurens NNZ-2591Feb 14, 2021
  • Quarterly report and cash flow statement for Q4 2020Jan 28, 2021
  • European Commission grants 3 NNZ-2591 Orphan designationsJan 10, 2021
  • Positive opinion for all 3 Orphan applications in EuropeDec 6, 2020
  • Approval received for final stage of NNZ-2591 clinical trialNov 18, 2020

Later from Neuren Pharmaceuticals

  • Preliminary Final Report and 2020 full year accountsFeb 23, 2021
  • Neuren approaching transforming milestones in 2021Feb 23, 2021
  • Neuren successfully completes manufacturing for Phase 2Mar 9, 2021
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021
  • Quarterly report and cash flow statement for Q1 2021Apr 22, 2021
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer